Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations

Saturday, November 4, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

- Dr. Froland brings over 20 years of pharmaceutical industry experience to the company -

SAN FRANCISCO, Nov. 3, 2017 /PRNewswire/ --áSymic Bio, a biopharmaceutical company developing novel matrix-targeting

biotherapeutics, announced today the appointment of Wayne Froland, Ph.D., as Executive Vice President of Technical Operations. Dr. Froland has over 20 years of experience in industry primarily focusing on process development in biopharmaceutical manufacturing.

"Dr. Froland will play an integral role at Symic as we build our capabilities for potential commercial-scale manufacturing," said Ken Horne, Symic Bio's Chief Executive Officer. "His experience with peptide biochemistry will be extremely helpful in satisfying the requirements for production of our novel category of therapeutics targeting the extracellular matrix."

"Symic Bio represents an extraordinary opportunity of bringing a novel class of therapeutics focused on the biology of the extracellular matrix to underserved areas of medical need," commented Dr. Froland. "The Symic Team has already progressed two programs into mid-stage clinical development and I am very excited to join them in accelerating the further development of these novel therapeutics through the commercialization process and into the hands of physicians and their patients."

Dr. Froland was most recently Associate Vice President at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization and manufacturing strategy. He has previously worked at Calypte Biomedical, Questcor Pharmaceuticals, Bayer Pharmaceuticals and Aerovance. Dr. Froland is the co-inventor on three patents related to synthesis of therapeutic peptides and has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology. He received his Ph.D. in Biochemistry from the University of Minnesota Medical School and conducted post-doctoral research at the Department of Chemistry, University of California, Berkeley.

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

á

View original content:http://www.prnewswire.com/news-releases/symic-bio-appoints-wayne-froland-phd-as-executive-vice-president-of-technical-operations-300549284.html

SOURCE Symic Bio



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store